US20010039283A1 - Compounds useful for inhibition of farnesyl protein transferase - Google Patents

Compounds useful for inhibition of farnesyl protein transferase Download PDF

Info

Publication number
US20010039283A1
US20010039283A1 US09/825,650 US82565001A US2001039283A1 US 20010039283 A1 US20010039283 A1 US 20010039283A1 US 82565001 A US82565001 A US 82565001A US 2001039283 A1 US2001039283 A1 US 2001039283A1
Authority
US
United States
Prior art keywords
compound
formula
alkyl
aryl
piperdinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/825,650
Inventor
Alan Cooper
Ronald Doll
Anil Saksena
Viyyoor Girijavallabhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/825,650 priority Critical patent/US20010039283A1/en
Publication of US20010039283A1 publication Critical patent/US20010039283A1/en
Priority to US10/235,027 priority patent/US6689789B2/en
Priority to US10/774,562 priority patent/US20040157872A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • WO 95/10516 published Apr. 20, 1995 discloses tricyclic compounds useful for inhibiting farnesyl protein transferase.
  • This invention provides compounds useful for the inhibition of farnesyl protein transferase (FPT).
  • FPT farnesyl protein transferase
  • a represents N or NO ⁇ ;
  • R 1 and R 3 are the same or different and each represents halo
  • R 2 and R 4 are the same or different and each is selected from H and halo, provided that at least one of R 2 and R 4 is H;
  • T is a substituent selected from SO 2 R or
  • Z is O or S
  • n is zero or an integer from 1 to 6;
  • R is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or N(R 5 ) 2 ;
  • R 5 is H, alkyl, aryl, heteroaryl or cycloalkyl.
  • the compounds of this invention (i) potently inhibit farnesyl protein transferase, but not geranylgeranyl protein transferase I, in vitro; (ii) block the phenotypic change induced by a form of transforming Ras which is a farnesyl acceptor but not by a form of transforming Ras engineered to be a geranylgeranyl acceptor; (iii) block intracellular processing of Ras which is a farnesyl acceptor but not of Ras engineered to be a geranylgeranyl acceptor; and (iv) block abnormal cell growth in culture induced by transforming Ras.
  • the compounds of this invention inhibit farnesyl protein transferase and the farnesylation of the oncogene protein Ras.
  • this invention further provides a method of inhibiting farnesyl protein transferase, (e.g., ras farnesyl protein transferase) in mammals, especially humans, by the administration of an effective amount of the compounds of formula 1.0.
  • the administration of the compounds of this invention to patients, to inhibit farnesyl protein transferase is useful in the treatment of the cancers described below.
  • This invention provides a method for inhibiting or treating the abnormal growth of cells, including transformed cells, by administering an effective amount of a compound of this invention.
  • Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) expressing an activated Ras oncogene; (2) tumor cells in which the Ras protein is activated as a result of oncogenic mutation in another gene; and (3) benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs.
  • This invention also provides a method for inhibiting or treating tumor growth by administering an effective amount of the tricyclic compounds, described herein, to a mammal (e.g., a human) in need of such treatment.
  • a mammal e.g., a human
  • this invention provides a method for inhibiting or treating the growth of tumors expressing an activated Ras oncogene by the administration of an effective amount of the compounds of formula 1.0.
  • tumors which may be inhibited or treated include, but are not limited to, lung cancer (e.g., lung adenocarcinoma), pancreatic cancers (e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma), colon cancers (e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), bladder carcinoma, epidermal carcinoma, breast cancer and prostate cancer.
  • lung cancer e.g., lung adenocarcinoma
  • pancreatic cancers e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma
  • colon cancers e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma
  • this invention also provides a method for inhibiting or treating proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes—i.e., the Ras gene itself is not activated by mutation to an oncogenic form—with said inhibition or treatment being accomplished by the administration of an effective amount of a compound of formula 1.0 to a mammal (e.g., a human) in need of such treatment.
  • a mammal e.g., a human
  • the benign proliferative disorder neurofibromatosis, or tumors in which Ras is activated due to mutation or overexpression of tyrosine kinase oncogenes may be inhibited or treated by the tricyclic compounds described herein.
  • the compounds of formula 1.0 useful in the methods of this invention inhibit or treat the abnormal growth of cells. Without wishing to be bound by theory, it is believed that these compounds may function through the inhibition of G-protein function, such as ras p21, by blocking G-protein isoprenylation, thus making them useful in the treatment of proliferative diseases such as tumor growth and cancer. Without wishing to be bound by theory, it is believed that these compounds inhibit ras farnesyl protein transferase, and thus show antiproliferative activity against ras transformed cells.
  • MH + represents the molecular ion plus hydrogen of the molecule in the mass spectrum
  • heterocycloalkyl represents a saturated, branched or unbranched carbocylic ring containing from 3 to 15 carbon atoms, preferably from 4 to 6 carbon atoms, which carbocyclic ring is interrupted by 1 to 3 hetero groups selected from —O—, —S— or —NR 9 —
  • R 9 can be, for example, —C(O)N(R 10 ) 2 , —CH 2 C(O)N(R 10 ) 2 , —SO 2 R 10 , —SO 2 N(R 10 ) 2 , —C(O)R 11 , —C(O)—O—R 11 , alkyl, aryl, aralkyl, cycloalkyl, heterocycloalkyl or heteroaryl; each R 10 independently represents H, alkyl, aryl, or aralkyl (e.g., benzyl); and R 11 is alkyl, aryl, aralkyl,
  • aryl (including the aryl portion of aryloxy and aralkyl)-represents a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g., aryl is a phenyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted (e.g., 1 to 3) with one or more of halo, alkyl, hydroxy, alkoxy, phenoxy, CF 3 , amino, alkylamino, dialkylamino, —COOR 11 or —NO 2 (wherein R 11 is H, alkyl, aryl, heteroaryl or cycloalkyl); and
  • Preferred halo atoms for R 1 , R 2 , R 3 , and R 4 in formula 1.0 are selected from: Br, Cl or I, with Br and Cl being preferred.
  • Compounds of formula 1.0 include compounds of the formula:
  • R 1 and R 3 are the same or different halo and a and T are as defined above.
  • R 1 and R 3 are independently selected from Br or Cl, and more preferably R 1 is Br and R 3 is Cl.
  • Compounds of formula 1.0 include compounds of formulas 1.1 and 1.2:
  • R 1 , R 3 and R 4 in formula 1.1 are halo
  • R 1 , R 2 and R 3 in formula 1.2 are halo.
  • Compounds of formula 1.1 are preferred.
  • R 1 is Br, R 3 is Cl, and R 4 is halo. More preferably, in formula 1.1, R 1 is Br, R 3 is Cl, and R 4 is Br.
  • R 1 is Br
  • R 2 is halo
  • R 3 is Cl
  • R 1 is Br
  • R 2 is Br
  • R 3 is Cl
  • T is preferably —SO 2 methyl or a group
  • R is a 3-pydinyl N-oxide, 4-pyridinyl N-oxide, 4-piperdinyl, 3-piperdinyl or 3-pyrrolidinyl group, wherein the 4-piperdinyl, 3-piperdinyl or 3-pyrrolidinyl groups may be substituted on the piperindinyl or pyrrolidinyl nitrogen with a group R 9 which can be, for example, —C(O)N(R 10 ) 2 , —CH 2 C(O)N(R 10 ) 2 , —SO 2 R 10 , —SO 2 N(R 10 ) 2 , —C(O)R 11 , —C(O)OR 11 , alkyl, aryl, aralkyl, cycloalkyl, heterocycloalkyl or heteroaryl; each R 10 independently represents H, alkyl, aryl, or aralkyl (e.g., benzyl); and R 11 is al
  • compounds of the invention include compounds of the formulas:
  • Certain compounds of the invention may exist in different isomeric (e.g., enantiomers and diastereoisomers) forms.
  • the invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures. Enol forms are also included.
  • Certain compounds of formula 1.0 will be acidic in nature, e.g. those compounds which possess a carboxyl or phenolic hydroxyl group. These compounds may form pharmaceutically acceptable salts. Examples of such salts may include sodium, potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.
  • Certain basic compounds of formula 1.0 also form pharmaceutically acceptable salts, e.g., acid addition salts.
  • the pyrido-nitrogen atoms may form salts with strong acid, while compounds having basic substituents such as amino groups also form salts with weaker acids.
  • suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methane-sulfonic and other mineral and carboxylic acids well known to those in the art.
  • the salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner.
  • the free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate.
  • a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate.
  • the free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the invention.
  • Intermdiates useful in the preparation of the compounds of the invention may be prepared according to the procedures described in WO 95/10516 published Apr. 20, 1995, in WO 96/30363 published Oct. 3, 1996, in U.S. Pat. No. 5,151,423 and by the methods described below.
  • the carboxylic acid (14.0) is coupled to the tricyclic amine (13.0) using amide bond forming conditions well known to those skilled in the art.
  • the substituents are as defined for Formula 1.0.
  • carbodiimide coupling methods e.g., DEC
  • the carboxylic acid (14.0) can be reacted with the tricyclic amine (13.0) using DEC/HOBT/NMM in DMF at about 25° C. for a sufficient period of time, e.g., about 18 hours, to produce a compound of Formula 1.0.
  • T is SO 2 R
  • X is halo, preferably, chloro.
  • the tricyclic piperadine compound is dissolved in an appropriate solvent such as DMF of THF.
  • a base is added such as triethylamine, and the appropriate alkylsulfonylchloride, prepared by methods known in the art, is added to the reaction mixture at 0° C. to ambient temperature with stirring. After 1-24 hours, the reaction mixture is added to water and the product extracted with a suitable solvent such as ethylacetate. The crude reaction product can then be chromatographed on a silica gel column.
  • Alkylaminosulfonamido derivatives can be prepared similarly:
  • R 5 groups may be the same or different and each is as defined above.
  • the tricyclic piperadine compound is dissolved in an appropriate solvent such as DMF of THF.
  • a base is added such as triethylamine, and the appropriate alkylaminosulfonylchloride, prepared by methods known in the art, is added to the reaction mixture at 0° C. to ambient temperature with stirring.
  • the reaction mixture is added to water and the product extracted with a suitable solvent such as ethylacetate.
  • the crude reaction product can then be chromatographed on a silica gel column.
  • carboxylic acids (14.0) and the sulfonates (14.2) are generally known in the art or can be prepared by methods well known in the literature.
  • R 6 is H, alkyl, carboalkoxy or any other group that can be converted into a group T.
  • the compounds of formula 13.0a are prepared by methods known in the art, for example, by methods disclosed in WO 95/10516, in WO 96/30363 published Oct. 3, 1996, in U.S. Pat. No. 5,151,423 and those described below.
  • the double bond in the compounds of formula 13.0a can be cleaved by oxidation, e.g., by the method in Preparative Example 3 below, to give the ketones of formula 15.0 below:
  • R 5a is hydrogen and R 6a is C 1 -C 6 alkyl, aryl or heteroaryl; R 5a is C 1 -C 6 alkyl, aryl or heteroaryl and R 6a is hydrogen; R 5a and R 6a are independently selected from the group consisting of C 1 -C 6 alkyl and aryl; or R 5a and R 6a , together with the nitrogen to which they are attached, form a ring comprising 4 to 6 carbon atoms or comprising 3 to 5 carbon atoms and one hetero moiety selected from the group consisting of —O— and —NR 9a —, wherein R 9a is H, C 1 -C 6 alkyl or phenyl;
  • R 2 , R 3 , and R 4 are as defined above and R 7a is Cl or Br, in the presence of a strong base to obtain a compound of the formula
  • step (b) reacting a compound of step (a) with POCl 3 to obtain a cyano compound of the formula
  • L is halo selected from the group consisting of Cl and Br, to obtain a ketone of the formula below:
  • R 1 , R 2 , R 3 and R 4 are as defined above, can be prepared by the following process comprising:
  • step (c) cyclizing a compound of step (b) with a reagent of the formula R 8a MgL, wherein R 8a is C 1 -C 8 alkyl, aryl or heteroaryl and L is Br or Cl, provided that prior to cyclization, compounds wherein R 5a or R 6a is hydrogen are reacted with a suitable N-protecting group.
  • Compounds of Formula 1.0 wherein substituent a is NO (Ring I) can be made from compounds of Formula 13.0a using procedures well known to those skilled in the art.
  • the compound of Formula 13.0a can be reacted with m-chloroperoxybenzoic acid in a suitable organic solvent, e.g., dichloromethane (usually anhydrous) or methylene chloride, at a suitable temperature, to produce a compound of Formula 13.0b
  • the organic solvent solution of Formula 13.0a is cooled to about 0° C. before the m-chloroperoxybenzoic acid is added.
  • the reaction is then allowed to warm to room temperature during the reaction period.
  • the desired product can be recovered by standard separation means.
  • the reaction mixture can be washed with an aqueous solution of a suitable base, e.g., saturated sodium bicarbonate or NaOH (e.g., 1N NaOH), and then dried over anhydrous magnesium sulfate.
  • the solution containing the product can be concentrated in vacuo.
  • the product can be purified by standard means, e.g., by chromatography using silica gel (e.g., flash column chromatography).
  • compounds of Formula 1.0 wherein substituent a is NO, can be made from compounds of Formula 1.0, wherein substituent a is N, by the m-chloroperoxybenzoic acid oxidation procedure described above.
  • Compounds of formula 1.0 wherein Z is S can be prepared from compounds of formula 1.0 wherein Z is O by treatment with a suitable sulfur transfer reagent such as Lawsson's reagent.
  • Compounds of the invention having asymmetric carbons can be separated into enantiomers by techniques known in the art, e.g., by chiral salt resolution or by chiral HPLC.
  • Example 1 The procedure of Example 1 above was followed replacing 4-pyridylacetic acid-N-oxide with N-Boc-4-piperadineacetic acid to obtain 4-(3,10-dibromo-8-chloro-6,11-dihydro-11-hydroxy-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-(N-BOC-4-piperdinylacetyl)piperidine in 85% yield.
  • High resolution MS: observed 712.0975
  • Carboxylic Acid T in Formula 1.0 HOOCCH 2 CONH 2 —OCCH 2 CONH 2 HOOCCH 2 CO 2 H —OCCH 2 CO 2 H HOOCCH 2 NH 2 —OCCH 2 NH 2 HOOCCH 2 —COOH —OCCH 2 —COOH
  • FPT IC 50 (inhibition of farnesyl protein transferase, in vitro enzyme assay) and COS Cell IC 50 (Cell-Based Assay) were determined following the assay procedures described in WO 95/10516, published Apr. 20, 1995.
  • GGPT IC 50 (inhibition of geranylgeranyl protein transferase, in vitro enzyme assay), Cell Mat Assay, and anti-tumor activity (in vivo anti-tumor studies) could be determined by the assay procedures described in WO 95/10516.
  • the disclosure of WO 95/10516 is incorporated herein by reference thereto.
  • Additional assays can be carried out by following essentially the same procedure as described above, but with substitution of alternative indicator tumor cell lines in place of the T24-BAG cells.
  • the assays can be conducted using either DLD-1-BAG human colon carcinoma cells expressing an activated K-ras gene or SW620-BAG human colon carcinoma cells expressing an activated K-ras gene.
  • the activity of the compounds of this invention against other types of cancer cells could be demonstrated.
  • Anchorage-independent growth is a characteristic of tumorigenic cell lines.
  • Human tumor cells are suspended in growth medium containing 0.3% agarose and an indicated concentration of a farnesyl transferase inhibitor.
  • the solution is overlayed onto growth medium solidified with 0.6% agarose containing the same concentration of farnesyl transferase inhibitor as the top layer. After the top layer is solidified, plates are incubated for 10-16 days at 37° C. under 5% CO 2 to allow colony outgrowth.
  • MTT 3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide, Thiazolyl blue
  • Colonies can be counted and the IC 50 's can be determined.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • the powders and tablets may be comprised of from about 5 to about 70 percent active ingredient.
  • Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
  • Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection.
  • Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.
  • a pharmaceutically acceptable carrier such as an inert compressed gas.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
  • liquid forms include solutions, suspensions and emulsions.
  • the compounds of the invention may also be deliverable transdermally.
  • the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • the compound is administered orally.
  • the pharmaceutical preparation is in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg. to 300 mg, according to the particular application.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
  • the amount and frequency of administration of the compounds of the invention and the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated.
  • a typical recommended dosage regimen is oral administration of from 10 mg to 2000 mg/day preferably 10 to 1000 mg/day, in two to four divided doses to block tumor growth.
  • the compounds are non-toxic when administered within this dosage range.
  • Tablets No. Ingredients mg/tablet mg/tablet 1. Active compound 100 500 2. Lactose USP 122 113 3. Corn Starch, Food Grade, 30 40 as a 10% paste in Purified Water 4. Corn Starch, Food Grade 45 40 5. Magnesium Stearate 3 7 Total 300 700

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel compounds of the formula:
Figure US20010039283A1-20011108-C00001
or a pharmaceutically acceptable salt or solvate thereof, wherein:
a represents N or NO−;
R1 and R3 are the same or different and each represents halo;
R2 and R4 are the same or different and each is selected from H and halo, provided that at least one of R2 and R4 is H;
T is a substituent selected from SO2R or
Figure US20010039283A1-20011108-C00002
Z is O or S;
n is zero or an integer from 1 to 6;
R is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or N(R5)2;
R5 is H, alkyl, aryl, heteroaryl or cycloalkyl.
Also disclosed are methods of inhibiting farnesyl protein transferase and methods for treating tumor cells.

Description

    BACKGROUND
  • WO 95/10516, published Apr. 20, 1995 discloses tricyclic compounds useful for inhibiting farnesyl protein transferase. [0001]
  • In view of the current interest in inhibitors of farnesyl protein transferase, a welcome contribution to the art would be compounds useful for the inhibition of farnesyl protein transferase. Such a contribution is provided by this invention. [0002]
    • SUMMARY OF THE INVENTION
  • This invention provides compounds useful for the inhibition of farnesyl protein transferase (FPT). The compounds of this invention are represented by the formula: [0003]
    Figure US20010039283A1-20011108-C00003
  • or a pharmaceutically acceptable salt or solvate thereof, wherein: [0004]
  • a represents N or NO[0005] −;
  • R[0006] 1 and R3 are the same or different and each represents halo;
  • R[0007] 2 and R4 are the same or different and each is selected from H and halo, provided that at least one of R2 and R4 is H;
  • T is a substituent selected from SO[0008] 2R or
    Figure US20010039283A1-20011108-C00004
  • Z is O or S; [0009]
  • n is zero or an integer from 1 to 6; [0010]
  • R is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or N(R[0011] 5)2;
  • R[0012] 5 is H, alkyl, aryl, heteroaryl or cycloalkyl.
  • The compounds of this invention: (i) potently inhibit farnesyl protein transferase, but not geranylgeranyl protein transferase I, in vitro; (ii) block the phenotypic change induced by a form of transforming Ras which is a farnesyl acceptor but not by a form of transforming Ras engineered to be a geranylgeranyl acceptor; (iii) block intracellular processing of Ras which is a farnesyl acceptor but not of Ras engineered to be a geranylgeranyl acceptor; and (iv) block abnormal cell growth in culture induced by transforming Ras. [0013]
  • The compounds of this invention inhibit farnesyl protein transferase and the farnesylation of the oncogene protein Ras. Thus, this invention further provides a method of inhibiting farnesyl protein transferase, (e.g., ras farnesyl protein transferase) in mammals, especially humans, by the administration of an effective amount of the compounds of formula 1.0. The administration of the compounds of this invention to patients, to inhibit farnesyl protein transferase, is useful in the treatment of the cancers described below. [0014]
  • This invention provides a method for inhibiting or treating the abnormal growth of cells, including transformed cells, by administering an effective amount of a compound of this invention. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) expressing an activated Ras oncogene; (2) tumor cells in which the Ras protein is activated as a result of oncogenic mutation in another gene; and (3) benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs. [0015]
  • This invention also provides a method for inhibiting or treating tumor growth by administering an effective amount of the tricyclic compounds, described herein, to a mammal (e.g., a human) in need of such treatment. In particular, this invention provides a method for inhibiting or treating the growth of tumors expressing an activated Ras oncogene by the administration of an effective amount of the compounds of formula 1.0. Examples of tumors which may be inhibited or treated include, but are not limited to, lung cancer (e.g., lung adenocarcinoma), pancreatic cancers (e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma), colon cancers (e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), bladder carcinoma, epidermal carcinoma, breast cancer and prostate cancer. [0016]
  • It is believed that this invention also provides a method for inhibiting or treating proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes—i.e., the Ras gene itself is not activated by mutation to an oncogenic form—with said inhibition or treatment being accomplished by the administration of an effective amount of a compound of formula 1.0 to a mammal (e.g., a human) in need of such treatment. For example, the benign proliferative disorder neurofibromatosis, or tumors in which Ras is activated due to mutation or overexpression of tyrosine kinase oncogenes (e.g., neu, src, abl, lck, and fyn), may be inhibited or treated by the tricyclic compounds described herein. [0017]
  • The compounds of formula 1.0 useful in the methods of this invention inhibit or treat the abnormal growth of cells. Without wishing to be bound by theory, it is believed that these compounds may function through the inhibition of G-protein function, such as ras p21, by blocking G-protein isoprenylation, thus making them useful in the treatment of proliferative diseases such as tumor growth and cancer. Without wishing to be bound by theory, it is believed that these compounds inhibit ras farnesyl protein transferase, and thus show antiproliferative activity against ras transformed cells. [0018]
    • DETAILED DESCRIPTION OF THE INVENTION
  • As used herein, the following terms are used as defined below unless otherwise indicated: [0019]
  • MH[0020] +-represents the molecular ion plus hydrogen of the molecule in the mass spectrum;
  • Et (or ET)-represents ethyl (C[0021] 2H5);
  • alkyl-represents straight and branched carbon chains that contain from one to twenty carbon atoms, preferably one to six carbon atoms; [0022]
  • halo-represents fluoro, chloro, bromo and iodo; [0023]
  • cycloalkyl-represents saturated carbocyclic rings branched or unbranched of from 3 to 20 carbon atoms, preferably 3 to 7 carbon atoms; [0024]
  • heterocycloalkyl-represents a saturated, branched or unbranched carbocylic ring containing from 3 to 15 carbon atoms, preferably from 4 to 6 carbon atoms, which carbocyclic ring is interrupted by 1 to 3 hetero groups selected from —O—, —S— or —NR[0025] 9— (wherein R9 can be, for example, —C(O)N(R10)2, —CH2C(O)N(R10)2, —SO2R10, —SO2N(R10)2, —C(O)R11, —C(O)—O—R11, alkyl, aryl, aralkyl, cycloalkyl, heterocycloalkyl or heteroaryl; each R10 independently represents H, alkyl, aryl, or aralkyl (e.g., benzyl); and R11 is alkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl)—(suitable heterocycloalkyl groups include 2- or 3-tetrahydrofuranyl, 2- or 3- tetrahydrothienyl, 2-, 3- or 4-piperidinyl, 2- or 3-pyrrolidinyl, 2- or 3-piperizinyl, 2- or 4-dioxanyl, etc.—with preferred heterocycloalkyl groups being 2-, 3- or 4-piperidinyl substituted with R10 on the piperidinyl nitrogen);
  • aryl (including the aryl portion of aryloxy and aralkyl)-represents a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g., aryl is a phenyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted (e.g., 1 to 3) with one or more of halo, alkyl, hydroxy, alkoxy, phenoxy, CF[0026] 3, amino, alkylamino, dialkylamino, —COOR11 or —NO2 (wherein R11 is H, alkyl, aryl, heteroaryl or cycloalkyl); and
  • heteroaryl-represents cyclic groups, optionally substituted with R[0027] 3 and R4, having at least one heteroatom selected from O, S or N, said heteroatom interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, with the aromatic heterocyclic groups preferably containing from 2 to 14 carbon atoms, e.g., triazolyl, 2-, 3- or 4-pyridyl or pyridyl N-oxide (optionally substituted with R11 as defined above), wherein pyridyl N-oxide can be represented as:
    Figure US20010039283A1-20011108-C00005
  • The following solvents and reagents are referred to herein by the abbreviations indicated: ethanol (EtOH); methanol (MeOH); acetic acid (HOAc or AcOH); ethyl acetate (EtOAc); N,N-dimethyl-formamide (DMF); trifluoroacetic acid (TFA); trifluoroacetic anhydride (TFAA); 1-hydroxybenzotriazole (HOBT); 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (DEC); diisobutylaluminum hydride(DIBAL); and 4-methylmorpholine (NMM). [0028]
  • The positions in the tricyclic ring system are: [0029]
    Figure US20010039283A1-20011108-C00006
  • Those skilled in the art will also appreciate that the S and R stereochemistry for the C-11 position of the tricyclic ring is as follows: [0030]
    Figure US20010039283A1-20011108-C00007
  • Preferred halo atoms for R[0031] 1, R2, R3, and R4 in formula 1.0 are selected from: Br, Cl or I, with Br and Cl being preferred.
  • Compounds of formula 1.0 include compounds of the formula: [0032]
    Figure US20010039283A1-20011108-C00008
  • wherein R[0033] 1 and R3 are the same or different halo and a and T are as defined above. Preferably, for these dihalo compounds, R1 and R3 are independently selected from Br or Cl, and more preferably R1 is Br and R3 is Cl.
  • Compounds of formula 1.0 include compounds of formulas 1.1 and 1.2: [0034]
    Figure US20010039283A1-20011108-C00009
  • wherein R[0035] 1, R3 and R4 in formula 1.1 are halo, and R1, R2 and R3 in formula 1.2 are halo. Compounds of formula 1.1 are preferred.
  • Preferably, in formula 1.1, R[0036] 1 is Br, R3 is Cl, and R4 is halo. More preferably, in formula 1.1, R1 is Br, R3 is Cl, and R4 is Br.
  • Preferably, in formula 1.2, R[0037] 1 is Br, R2 is halo, and R3 is Cl. More preferably, in formula 1.1, R1 is Br, R2 is Br, and R3 is Cl.
  • Also, preferably, for the compounds of this invention, substituent a in Ring I represents N. [0038]
  • T is preferably —SO[0039] 2methyl or a group
    Figure US20010039283A1-20011108-C00010
  • wherein R is a 3-pydinyl N-oxide, 4-pyridinyl N-oxide, 4-piperdinyl, 3-piperdinyl or 3-pyrrolidinyl group, wherein the 4-piperdinyl, 3-piperdinyl or 3-pyrrolidinyl groups may be substituted on the piperindinyl or pyrrolidinyl nitrogen with a group R[0040] 9 which can be, for example, —C(O)N(R10)2, —CH2C(O)N(R10)2, —SO2R10, —SO2N(R10)2, —C(O)R11, —C(O)OR11, alkyl, aryl, aralkyl, cycloalkyl, heterocycloalkyl or heteroaryl; each R10 independently represents H, alkyl, aryl, or aralkyl (e.g., benzyl); and R11 is alkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl.
  • Those skilled in the art will appreciate that compounds of formula 1.0 include compounds of formulas 1.3 and 1.4: [0041]
    Figure US20010039283A1-20011108-C00011
  • with compounds of 1.3 being preferred for compounds of formula 1.1, and with compounds of Formula 1.4 being preferred for compounds of formula 1.2. [0042]
  • Thus, compounds of the invention include compounds of the formulas: [0043]
    Figure US20010039283A1-20011108-C00012
  • Certain compounds of the invention may exist in different isomeric (e.g., enantiomers and diastereoisomers) forms. The invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures. Enol forms are also included. [0044]
  • Certain compounds of formula 1.0 will be acidic in nature, e.g. those compounds which possess a carboxyl or phenolic hydroxyl group. These compounds may form pharmaceutically acceptable salts. Examples of such salts may include sodium, potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like. [0045]
  • Certain basic compounds of formula 1.0 also form pharmaceutically acceptable salts, e.g., acid addition salts. For example, the pyrido-nitrogen atoms may form salts with strong acid, while compounds having basic substituents such as amino groups also form salts with weaker acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methane-sulfonic and other mineral and carboxylic acids well known to those in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate. The free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the invention. [0046]
  • All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention. [0047]
  • Intermdiates useful in the preparation of the compounds of the invention may be prepared according to the procedures described in WO 95/10516 published Apr. 20, 1995, in WO 96/30363 published Oct. 3, 1996, in U.S. Pat. No. 5,151,423 and by the methods described below. [0048]
  • Compounds of the invention can be prepared according to the reaction: [0049]
    Figure US20010039283A1-20011108-C00013
  • In the reaction, the carboxylic acid (14.0) is coupled to the tricyclic amine (13.0) using amide bond forming conditions well known to those skilled in the art. The substituents are as defined for Formula 1.0. For example, carbodiimide coupling methods (e.g., DEC) can be used. For example, the carboxylic acid (14.0) can be reacted with the tricyclic amine (13.0) using DEC/HOBT/NMM in DMF at about 25° C. for a sufficient period of time, e.g., about 18 hours, to produce a compound of Formula 1.0. [0050]
  • When T is SO[0051] 2R, X is halo, preferably, chloro.
    Figure US20010039283A1-20011108-C00014
  • The tricyclic piperadine compound is dissolved in an appropriate solvent such as DMF of THF. A base is added such as triethylamine, and the appropriate alkylsulfonylchloride, prepared by methods known in the art, is added to the reaction mixture at 0° C. to ambient temperature with stirring. After 1-24 hours, the reaction mixture is added to water and the product extracted with a suitable solvent such as ethylacetate. The crude reaction product can then be chromatographed on a silica gel column. [0052]
  • Alkylaminosulfonamido derivatives can be prepared similarly: [0053]
    Figure US20010039283A1-20011108-C00015
  • wherein the R[0054] 5groups may be the same or different and each is as defined above. In this reaction, the tricyclic piperadine compound is dissolved in an appropriate solvent such as DMF of THF. A base is added such as triethylamine, and the appropriate alkylaminosulfonylchloride, prepared by methods known in the art, is added to the reaction mixture at 0° C. to ambient temperature with stirring. After 1-24 hours, the reaction mixture is added to water and the product extracted with a suitable solvent such as ethylacetate. The crude reaction product can then be chromatographed on a silica gel column.
  • The carboxylic acids (14.0) and the sulfonates (14.2) are generally known in the art or can be prepared by methods well known in the literature. [0055]
  • Compounds of Formula 13.0 can be prepared from compounds of formula 13.0a: [0056]
    Figure US20010039283A1-20011108-C00016
  • wherein R[0057] 6 is H, alkyl, carboalkoxy or any other group that can be converted into a group T. The compounds of formula 13.0a are prepared by methods known in the art, for example, by methods disclosed in WO 95/10516, in WO 96/30363 published Oct. 3, 1996, in U.S. Pat. No. 5,151,423 and those described below.
  • The double bond in the compounds of formula 13.0a can be cleaved by oxidation, e.g., by the method in Preparative Example 3 below, to give the ketones of formula 15.0 below: [0058]
    Figure US20010039283A1-20011108-C00017
  • Compounds of Formula 13.0a wherein the C-3 postion of the pyridine ring in the tricyclic structure is substituted by bromo (i.e., R[0059] 1 is Br) can also be prepared by a procedure comprising the following steps:
  • (a) reacting an amide of the formula [0060]
    Figure US20010039283A1-20011108-C00018
  • wherein R[0061] 5a is hydrogen and R6a is C1-C6 alkyl, aryl or heteroaryl; R5a is C1-C6 alkyl, aryl or heteroaryl and R6a is hydrogen; R5a and R6a are independently selected from the group consisting of C1-C6 alkyl and aryl; or R5a and R6a, together with the nitrogen to which they are attached, form a ring comprising 4 to 6 carbon atoms or comprising 3 to 5 carbon atoms and one hetero moiety selected from the group consisting of —O— and —NR9a—, wherein R9a is H, C1-C6 alkyl or phenyl;
  • with a compound of the formula [0062]
    Figure US20010039283A1-20011108-C00019
  • wherein R[0063] 2, R3, and R4 are as defined above and R7a is Cl or Br, in the presence of a strong base to obtain a compound of the formula
    Figure US20010039283A1-20011108-C00020
  • (b) reacting a compound of step (a) with POCl[0064] 3 to obtain a cyano compound of the formula
    Figure US20010039283A1-20011108-C00021
  • (c) reacting the cyano compound with a piperidine derivative of the formula [0065]
    Figure US20010039283A1-20011108-C00022
  • wherein L is halo selected from the group consisting of Cl and Br, to obtain a ketone of the formula below: [0066]
    Figure US20010039283A1-20011108-C00023
  • (d)(i) cyclizing the ketone under acid conditions (e.g., aluminum chloride, triflic acid, or sulfuric acid) to obtain a compound of Formula 13.0a wherein R[0067] 6 is methyl, which can be cleaved to give the compound of formula 15.0,
  • Methods for preparing compounds of Formula 13.0a disclosed in WO 95/10516, in WO 96/30363 published Oct. 3, 1996, in U.S. Pat. No. 5,151,423 and described below employ a tricyclic ketone intermediate. Such intermediates of the formula [0068]
    Figure US20010039283A1-20011108-C00024
  • wherein R[0069] 1, R2, R3 and R4 are as defined above, can be prepared by the following process comprising:
  • (a) reacting a compound of the formula [0070]
    Figure US20010039283A1-20011108-C00025
  • (i) with an amine of the formula NHR[0071] 5aR6a, wherein R5a and R6a are as defined in the process above; in the presence of a palladium catalyst and carbon monoxide to obtain an amide of the formula:
    Figure US20010039283A1-20011108-C00026
  • or [0072]
  • (ii) with an alcohol of the formula R[0073] 10aOH, wherein R10a is C1-C6 lower alkyl or C3-C6 cycloalkyl, in the presence of a palladium catalyst and carbon monoxide to obtain the ester of the formula
    Figure US20010039283A1-20011108-C00027
  • followed by reacting the ester with an amine of formula NHR[0074] 5aR6a to obtain the amide;
  • (b) reacting the amide with an iodo-substituted benzyl compound of the formula [0075]
    Figure US20010039283A1-20011108-C00028
  • wherein R[0076] 2, R3, R4 and R7a are as defined above, in the presence of a strong base to obtain a compound of the formula
    Figure US20010039283A1-20011108-C00029
  • and [0077]
  • (c) cyclizing a compound of step (b) with a reagent of the formula R[0078] 8aMgL, wherein R8a is C1-C8 alkyl, aryl or heteroaryl and L is Br or Cl, provided that prior to cyclization, compounds wherein R5a or R6a is hydrogen are reacted with a suitable N-protecting group.
  • Compounds of Formula 1.0 wherein substituent a is NO (Ring I) can be made from compounds of Formula 13.0a using procedures well known to those skilled in the art. For example, the compound of Formula 13.0a can be reacted with m-chloroperoxybenzoic acid in a suitable organic solvent, e.g., dichloromethane (usually anhydrous) or methylene chloride, at a suitable temperature, to produce a compound of Formula 13.0b [0079]
    Figure US20010039283A1-20011108-C00030
  • which can then be cleaved to provide a compound of formula 15.0 above. [0080]
  • Generally, the organic solvent solution of Formula 13.0a is cooled to about 0° C. before the m-chloroperoxybenzoic acid is added. The reaction is then allowed to warm to room temperature during the reaction period. The desired product can be recovered by standard separation means. For example, the reaction mixture can be washed with an aqueous solution of a suitable base, e.g., saturated sodium bicarbonate or NaOH (e.g., 1N NaOH), and then dried over anhydrous magnesium sulfate. The solution containing the product can be concentrated in vacuo. The product can be purified by standard means, e.g., by chromatography using silica gel (e.g., flash column chromatography). [0081]
  • Alternatively, compounds of Formula 1.0, wherein substituent a is NO, can be made from compounds of Formula 1.0, wherein substituent a is N, by the m-chloroperoxybenzoic acid oxidation procedure described above. [0082]
  • Those skilled in the art will appreciate that it is preferable to avoid an excess of m-chloroperoxybenzoic acid when the oxidation reaction is carried out on the compounds of formula 13.0a. In these reactions an excess of m-chloroperoxybenzoic can cause oxidation of the C-11 double bond. [0083]
  • Compounds of formula 1.0 wherein Z is S can be prepared from compounds of formula 1.0 wherein Z is O by treatment with a suitable sulfur transfer reagent such as Lawsson's reagent. [0084]
  • Compounds of the invention having asymmetric carbons (e.g., compounds of the invention wherein X is CH or N have an asymmetric carbon at the C-11 position of the the tricyclic ring) can be separated into enantiomers by techniques known in the art, e.g., by chiral salt resolution or by chiral HPLC.[0085]
  • Compounds useful in this invention are exemplified by the following examples, which should not be construed to limit the scope of the disclosure. [0086]
    • Preparative Example 1
  • [0087]
    Figure US20010039283A1-20011108-C00031
  • 3,10-dibromo-8-chloro-6,11-dihydro-11-one-5H-benzo[5,6]-cycloheptyl-[1,2-b]pyridine (2 gm, 4.98 mmol) was dissolved in 20 ml of dry tetrahydrofuran under a dry nitrogen atmosphere. 5 ml of a 1.5 molar solution of N-methyl-piperidine-4-magnesium chloride was added and the reaction stirred for 18 hours. The reaction mixture was washed with saturated ammonium chloride, dried over magnesium sulfate, filtered and evaporated to a brown oil which was chromatographed on silica gel using 2.5% methanol/methylene chloride as the eluent to obtain 2.11 gm, 85% of 3,10-dibromo-8-chloro-6,11-dihydro-11-(1-methyl-4-piperidinyl)-5H-benzo[5,6]cycloheptyl[1,2-b]pyridin-11-ol. FABMS (M+H)=501 [0088]
    • Preparative Example 2
  • [0089]
    Figure US20010039283A1-20011108-C00032
  • Combine 25.86 g (55.9 mmol) of 4-(8-chloro-3-bromo-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-1-carboxylic acid ethyl ester and 250 mL of concentrated H[0090] 2SO4 at −5° C., then add 4.8 g (56.4 mmol) of NaNO3 and stir for 2 hours. Pour the mixture into 600 g of ice and basify with concentrated NH4OH (aqueous). Filter the mixture, wash with 300 mL of water, then extract with 500 mL of CH2Cl2. Wash the extract with 200 mL of water, dry over MgSO4, then filter and concentrate in vacuo to a residue. Chromatograph the residue (silica gel, 10% EtOAc/CH2Cl2) to give 24.4 g (86% yield) of the product. m.p.=165-167° C., Mass Spec.: MH+=506 (CI). Elemental analysis: calculated—C, 52.13; H, 4.17; N, 8.29; found—C, 52.18; H, 4.51; N, 8.16.
    Figure US20010039283A1-20011108-C00033
  • Combine 20 g (40.5 mmol) of the product of Step A and 200 mL of concentrated H[0091] 2SO4 at 20° C., then cool the mixture to 0° C. Add 7.12 g (24.89 mmol) of 1,3-dibromo-5,5-dimethyl-hydantoin to the mixture and stir for 3 hours at 20° C. Cool to 0° C., add an additional 1.0 g (3.5 mmol) of the dibromohydantoin and stir at 20° C. for 2 hours. Pour the mixture into 400 g of ice, basify with concentrated NH4OH (aqueous) at 0° C., and collect the resulting solid by filtration. Wash the solid with 300 mL of water, slurry in 200 mL of acetone and filter to provide 19.79 g (85.6% yield) of the product. m.p.=236-237° C., Mass Spec.: MH+=584 (CI). Elemental analysis: calculated—C, 45.11; H, 3.44; N, 7.17; found—C, 44.95; H, 3.57; N, 7.16
    Figure US20010039283A1-20011108-C00034
  • Combine 25 g (447 mmol) of Fe filings, 10 g (90 mmol) of CaCl[0092] 2 and a suspension of 20 g (34.19 mmol) of the product of Step B in 700 mL of 90:10 EtOH/water at 50° C. Heat the mixture at reflux overnight, filter through Celite® and wash the filter cake with 2×200 mL of hot EtOH. Combine the filtrate and washes, and concentrate in vacuo to a residue. Extract the residue with 600 mL of CH2Cl2, wash with 300 mL of water and dry over MgSO4. Filter and concentrate in vacuo to a residue, then chromatograph (silica gel, 30% EtOAc/CH2Cl2) to give 11.4 g (60% yield) of the product. m.p.=211-212° C., Mass Spec.: MH+=554 (CI). Elemental analysis: calculated—C, 47.55; H, 3.99; N, 7.56; found—C, 47.45; H, 4.31; N, 7.49.
    Figure US20010039283A1-20011108-C00035
  • Slowly add (in portions) 20 g (35.9 mmol) of the product of Step C to a solution of 8 g (116 mmol) of NaNO[0093] 2 in 120 mL of concentrated HCl (aqueous) at −10° C. Stir the resulting mixture at 0° C. for 2 hours, then slowly add (dropwise) 150 mL (1.44 mole) of 50% H3PO2 at 0° C. over a 1 hour period. Stir at 0° C. for 3 hours, then pour into 600 g of ice and basify with concentrated NH4OH (aqueous). Extract with 2×300 mL of CH2Cl2, dry the extracts over MgSO4, then filter and concentrate in vacuo to a residue. Chromatograph the residue (silica gel, 25% EtOAc/hexanes) to give 13.67 g (70% yield) of the product. m.p.=163-165° C., Mass Spec.: MH+=539 (CI). Elemental analysis: calculated—C, 48.97; H, 4.05; N, 5.22; found—C, 48.86; H, 3.91; N, 5.18.
    Figure US20010039283A1-20011108-C00036
  • Combine 6.8 g (12.59 mmol) of the product of Step D and 100 mL of concentrated HCl (aqueous) and stir at 85° C. overnight. Cool the mixture, pour it into 300 g of ice and basify with concentrated NH[0094] 4OH (aqueous). Extract with 2×300 mL of CH2Cl2, then dry the extracts over MgSO4. Filter, concentrate in vacuo to a residue, then chromatograph (silica gel, 10% MeOH/EtOAc+2% NH4OH (aqueous)) to give 5.4 g (92% yield) of the title compound. m.p.=172-174° C., Mass Spec.: MH+=467 (FAB). Elemental analysis: calculated—C, 48.69; H, 3.65; N, 5.97; found—C, 48.83; H, 3.80; N, 5.97
    • Preparative Example 3
  • [0095]
    Figure US20010039283A1-20011108-C00037
  • Combine 16.6 g (0.03 mole) of the product of Preparative Example 3, Step D, with a 3:1 solution of CH[0096] 3CN and water (212.65 mL CH3CN and 70.8 mL of water) and stir the resulting slurry overnight at room temperature. Add 32.833 g (0.153 mole) of NaIO4 and then 0.31 g (2.30 mmol) of RuO2 and stir at room temperature give 1.39 g (69% yield) of the product. (The addition of RuO is accompanied by an exothermic reaction and the temperature climbs from 20° to 30° C.) Stir the mixture for 1.3 hrs. (temperature returned to 25° C. after about 30 min.), then filter to remove the solids and wash the solids with CH2Cl2. Concentrate the filtrate in vacuo to a residue and dissolve the residue in CH2Cl2. Filter to remove insoluble solids and wash the solids with CH2Cl2. Wash the filtrate with water, concentrate to a volume of about 200 mL and wash with bleach, then with water. Extract with 6 N HCl (aqueous). Cool the aqueous extract to 0° C. and slowly add 50% NaOH (aqueous) to adjust to pH=4 while keeping the temperature <30° C. Extract twice with CH2Cl2, dry over MgSO4 and concentrate in vacuo to a residue. Slurry the residue in 20 mL of EtOH and cool to 0° C. Collect the resulting solids by filtration and dry the solids in vacuo to give 7.95 g of the product. 1H NMR (CDCl3, 200 MHz): 8.7 (s, 1H); 7.85 (m, 6H); 7.5 (d, 2H); 3.45 (m, 2H); 3.15 (m, 2H).
    • Preparative Example 4
  • [0097]
    Figure US20010039283A1-20011108-C00038
  • Combine 15 g (38.5 mmol) of 4-(8-chloro-3-bromo-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-1-carboxylic acid ethyl ester and 150 mL of concentrated H[0098] 2SO4 at −5° C., then add 3.89 g (38.5 mmol) of KNO3 and stir for 4 hours. Pour the mixture into 3 L of ice and basify with 50% NaOH (aqueous). Extract with CH2Cl2, dry over MgSO4, then filter and concentrate in vacuo to a residue. Recrystallize the residue from acetone to give 6.69 g of the product. 1H NMR (CDCl3, 200 MHz): 8.5 (s, 1H); 7.75 (s, 1H); 7.6 (s, 1H); 7.35 (s, 1H); 4.15 (q, 2H); 3.8 (m, 2H); 3.5-3.1 (m, 4H); 3.0-2.8 (m, 2H); 2.6-2.2 (m, 4H); 1.25 (t, 3H).
    Figure US20010039283A1-20011108-C00039
  • Combine 6.69 g (13.1 mmol) of the product of Step A and 100 mL of 85% EtOH/water, then add 0.66 g (5.9 mmol) of CaCl[0099] 2 and 6.56 g (117.9 mmol) of Fe and heat the mixture at reflux overnight. Filter the hot reaction mixture through celite® and rinse the filter cake with hot EtOH. Concentrate the filtrate in vacuo to give 7.72 g of the product. Mass Spec.: MH+=478.0
    Figure US20010039283A1-20011108-C00040
  • Combine 7.70 g of the product of Step B and 35 mL of HOAc, then add 45 mL of a solution of Br[0100] 2 in HOAc and stir the mixture at room temperature overnight. Add 300 mL of 1 N NaOH (aqueous), then 75 mL of 50% NaOH (aqueous) and extract with EtOAc. Dry the extract over MgSO4 and concentrate in vacuo to a residue. Chromatograph the residue (silica gel, 20%-30% EtOAc/hexane) to give 3.47 g of the product (along with another 1.28 g of partially purified product). Mass Spec.: MH+=555.9. 1H NMR (CDCl3, 300 MHz): 8.5 (s, 1H); 7.5 (s, 1H); 7.15 (s, 1H); 4.5 (s, 2H); 4.15 (m, 3H); 3.8 (br s, 2H); 3.4-3.1 (m, 4H); 9-2.75 (m, 1H); 2.7-2.5 (m, 2H); 2.4-2.2 (m, 2H); 1.25 (m, 3H).
    Figure US20010039283A1-20011108-C00041
  • Combine 0.557 g (5.4 mmol) of t-butylnitrite and 3 mL of DMF, and heat the mixture at to 60°-70° C. Slowly add (dropwise) a mixture of 2.00 g (3.6 mmol) of the product of Step C and 4 mL of DMF, then cool the mixture to room temperature. Add another 0.64 mL of t-butylnitrite at 40° C. and reheat the mixture to 60°-70° C. for 0.5 hrs. Cool to room temperature and pour the mixture into 150 mL of water. Extract with CH[0101] 2Cl2, dry the extract over MgSO4 and concentrate in vacuo to a residue. Chromatograph the residue (silica gel, 10%-20% EtOAc/hexane) to give 0.74 g of the product. Mass Spec.: MH+=541.0.
  • [0102] 1H NMR (CDCl3, 200 MHz): 8.52 (s, 1H); 7.5 (d, 2H); 7.2 (s, 1H); 4.15 (q, 2H); 3.9-3.7 (m, 2H); 3.5-3.1 (m, 4H); 3.0-2.5 (m, 2H); 2.4-2.2 (m, 2H); 2.1-1.9 (m, 2H); 1.26 (t, 3H).
    Figure US20010039283A1-20011108-C00042
  • Combine 0.70 g (1.4 mmol) of the product of Step D and 8 mL of concentrated HCl (aqueous) and heat the mixture at reflux overnight. Add 30 mL of 1 N NaOH (aqueous), then 5 mL of 50% NaOH (aqueous) and extract with CH[0103] 2Cl2. Dry the extract over MgSO4 and concentrate in vacuo to give 0.59 g of the title compound. Mass Spec.: M+=468.7. m.p.=123.9°-124.2° C.
  • The title compound can be cleaved by the methodology of Preparative Example 3 to prepare the corresponding 11-ketone having 3,10-dibromo-8-chloro substituents. [0104]
    • Preparative Example 5
  • [0105]
    Figure US20010039283A1-20011108-C00043
  • Combine 40.0 g (0.124 mole) of the starting ketone and 200 mL of H[0106] 2SO4 and cool to 0° C. Slowly add 13.78 g (0.136 mole) of KNO3 over a period of 1.5 hrs., then warm to room temperature and stir overnight. Work up the reaction using substantially the same procedure as described for Preparative Example 2, Step A. Chromatograph (silica gel, 20%, 30%, 40%, 50% EtOAc/hexane, then 100% EtOAc) to give 28 g of the 9-nitro product, along with a smaller quantity of the 7-nitro product and 19 g of a mixture of the 7-nitro and 9-nitro compounds.
    Figure US20010039283A1-20011108-C00044
  • React 28 g (76.2 mmol) of the 9-nitro product of Step A, 400 mL of 85% EtOH/water, 3.8 g (34.3 mmol) of CaCl[0107] 2 and 38.28 g (0.685 mole) of Fe using substantially the same procedure as described for Preparative Example 2, Step C, to give 24 g of the product
    Figure US20010039283A1-20011108-C00045
  • Combine 13 g (38.5 mmol) of the product of Step B, 140 mL of HOAc and slowly add a solution of 2.95 mL (57.8 mmol) of Br[0108] 2 in 10 mL of HOAc over a period of 20 min. Stir the reaction mixture at room temperature, then concentrate in vacuo to a residue. Add CH2Cl2 and water, then adjust to pH=8-9 with 50% NaOH (aqueous). Wash the organic phase with water, then brine and dry over Na2SO4. Concentrate in vacuo to give 11.3 g of the product.
    Figure US20010039283A1-20011108-C00046
  • Cool 100 mL of concentrated HCl (aqueous) to 0° C., then add 5.61 g (81.4 mmol) of NaNO[0109] 2 and stir for 10 min. Slowly add (in portions) 11.3 g (27.1 mmol) of the product of Step C and stir the mixture at 0°-3° C. for 2.25 hrs. Slowly add (dropwise) 180 mL of 50% H3PO2 (aqueous) and allow the mixture to stand at 0° C. overnight. Slowly add (dropwise) 150 mL of 50% NaOH over 30 min., to adjust to pH=9, then extract with CH2Cl2. Wash the extract with water, then brine and dry over Na2SO4. Concentrate in vacuo to a residue and chromatograph (silica gel, 2% EtOAc/CH2Cl2) to give 8.6 g of the product.
    • Example 1
  • [0110]
    Figure US20010039283A1-20011108-C00047
  • The compound from Preparative Example 1 (0.95 gm, 1.9 mmol) was dissolved in 34 ml of toluene. Triethylamine (1 ml) and ethylchloroformate (1.82 ml, 10 eq.) were added and the reaction mixture refluxed for two hours. The reaction mixture was cooled to ambient temperature and evaporated to an oil. The oil was chromatographed on silica gel using 15 to 20% ethylacetate/hexanes to obtain 0.77 gm of ethyl 4-(3,10-dibromo-8-chloro-6,11-dihydro-11-hydroxy-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate. FABMS (M+H)=559 [0111]
    Figure US20010039283A1-20011108-C00048
  • The compound from Preparative Example 2 (0.37 gm) was dissolved in 5 ml of concentrated hydrochloric acid and refluxed for 18 hours. The mixture was evaporated to a brown solid of the compound 4-(3,10-dibromo-8-chloro-6,11-dihydro-11-hydroxy-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidine and used without chromatography. [0112]
    Figure US20010039283A1-20011108-C00049
  • The compound of Preparative Example 3 (100 mg, 0.206 mmol) was dissolved in 2 ml of N,N-dimethylformamide. 4-Pyridylacetic acid-N-oxide (126 mg, 0.82 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (DEC) (0.079 mg, 0.5 mmol)), 1-hydroxybenzotriazole (HOBt) (0.056 gm, 0.5 mmol), and N-methylmorpholine (0.23 ml, 2.0 mmol) were added and the reaction mixture stirred at ambient temperature. After 24 hours, the reaction mixture was added to brine and extracted with 3×15 ml of ethylacetate. The combined ethylacetate washes were combined and the solvent evaporated under vacuo to give a gum. The gum was chromatographed flash silica gel using 10% methanol/methylenechloride as the eluent to obtain 0.076 gm of 4-(3,10-dibromo-8-chloro-6,11-dihydro-11-hydroxy-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl) -1-(4-pyridinylacetyl)piperidine N1-oxide. FABMS (M+H)=622 [0113]
    • Example 2
  • [0114]
    Figure US20010039283A1-20011108-C00050
  • The procedure of Example 1 above was followed replacing 4-pyridylacetic acid-N-oxide with N-Boc-4-piperadineacetic acid to obtain 4-(3,10-dibromo-8-chloro-6,11-dihydro-11-hydroxy-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-(N-BOC-4-piperdinylacetyl)piperidine in 85% yield. High resolution MS: observed=712.0975 [0115]
    Figure US20010039283A1-20011108-C00051
  • The compound of Step A above (0.21 gm) was dissolved in 50% trifluoroacetic acid/methylenechloride and stirred for 1 hour. The reaction mixture was evaporated to obtain an oil which was dissolved in 2 ml of methylenechloride to provide 4-[2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-11-hydroxy-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-yl)-1-piperdinyl]-2-oxoethyl]-1-piperidine. [0116]
    Figure US20010039283A1-20011108-C00052
  • Trimethylsilylisocyanate (234 ul, 1.47 mmol) was added and the reaction mixture stirred at ambient temperature for 15 hours. The solvent was evaporated and the crude product chromatographed on silica gel using 7.5% methanol/methylenechloride to obtain 100 mg, 62% of 4-[2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-11-hydroxy-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperdinyl]-2-oxoethyl]-1-piperidinecarboxamide. High resolution MS: observed=655.0509 [0117]
    • Example 3
  • [0118]
    Figure US20010039283A1-20011108-C00053
  • The compound of Example 2 Step A above (0.069 g, 0.113 mmol) was dissolved in 2 ml of N,N-dimethylformamide. Sodium carbonate (0.036 g, 0.34 mmol) and bromoacetamide (0.023 g, 0.17 mmol) were added and the reaction mixture stirred at ambient temperature for 24 hours. The mixture was added to brine and extracted with ethylacetate. The ethylacetate layer was dried over magnesium sulfate, filtered and evaporated to obtain a crude solid. The crude solid was chromatographed on silica gel using 5% methanol/methylenechloride to obtain 4-[2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-11-hydroxy-5H-benzo[5,6]cyclohepta-[1,2-B]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidineacetamide. High resolution MS: observed=669.0666 [0119]
  • The following compounds can be prepared utilizing the procedure of Example 1 above and substituting the following carboxylic acids for 4-pyridylacetic acid-N-oxide. [0120]
    Carboxylic Acid T = in Formula 1.0
    HOOCCH2CONH2 —OCCH2CONH2
    Figure US20010039283A1-20011108-C00054
    Figure US20010039283A1-20011108-C00055
    HOOCCH2CO2H —OCCH2CO2H
    Figure US20010039283A1-20011108-C00056
    Figure US20010039283A1-20011108-C00057
    Figure US20010039283A1-20011108-C00058
    Figure US20010039283A1-20011108-C00059
    Figure US20010039283A1-20011108-C00060
    Figure US20010039283A1-20011108-C00061
    Figure US20010039283A1-20011108-C00062
    Figure US20010039283A1-20011108-C00063
    Figure US20010039283A1-20011108-C00064
    Figure US20010039283A1-20011108-C00065
    HOOCCH2NH2 —OCCH2NH2
    Figure US20010039283A1-20011108-C00066
    Figure US20010039283A1-20011108-C00067
    Figure US20010039283A1-20011108-C00068
    Figure US20010039283A1-20011108-C00069
    Figure US20010039283A1-20011108-C00070
    Figure US20010039283A1-20011108-C00071
    HOOCCH2—COOH —OCCH2—COOH
    Figure US20010039283A1-20011108-C00072
    Figure US20010039283A1-20011108-C00073
    Figure US20010039283A1-20011108-C00074
    Figure US20010039283A1-20011108-C00075
    Figure US20010039283A1-20011108-C00076
    Figure US20010039283A1-20011108-C00077
    • ASSAYS
  • FPT IC[0121] 50 (inhibition of farnesyl protein transferase, in vitro enzyme assay) and COS Cell IC50 (Cell-Based Assay) were determined following the assay procedures described in WO 95/10516, published Apr. 20, 1995. GGPT IC50 (inhibition of geranylgeranyl protein transferase, in vitro enzyme assay), Cell Mat Assay, and anti-tumor activity (in vivo anti-tumor studies) could be determined by the assay procedures described in WO 95/10516. The disclosure of WO 95/10516 is incorporated herein by reference thereto.
  • Additional assays can be carried out by following essentially the same procedure as described above, but with substitution of alternative indicator tumor cell lines in place of the T24-BAG cells. The assays can be conducted using either DLD-1-BAG human colon carcinoma cells expressing an activated K-ras gene or SW620-BAG human colon carcinoma cells expressing an activated K-ras gene. Using other tumor cell lines known in the art, the activity of the compounds of this invention against other types of cancer cells could be demonstrated. [0122]
  • Soft Agar Assay: [0123]
  • Anchorage-independent growth is a characteristic of tumorigenic cell lines. Human tumor cells are suspended in growth medium containing 0.3% agarose and an indicated concentration of a farnesyl transferase inhibitor. The solution is overlayed onto growth medium solidified with 0.6% agarose containing the same concentration of farnesyl transferase inhibitor as the top layer. After the top layer is solidified, plates are incubated for 10-16 days at 37° C. under 5% CO[0124] 2 to allow colony outgrowth. After incubation, the colonies are stained by overlaying the agar with a solution of MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide, Thiazolyl blue) (1 mg/mL in PBS). Colonies can be counted and the IC50's can be determined.
  • Results from the in vitro enzyme assay are given in Table 1. [0125]
    TABLE 1
    FPT IC50
    Example No. Compound (μM)
    #1 Step C
    Figure US20010039283A1-20011108-C00078
         		<0.002
    #2 Step C
    Figure US20010039283A1-20011108-C00079
         		0.0108
    #2 Step A
    Figure US20010039283A1-20011108-C00080
         		0.042
    #3
    Figure US20010039283A1-20011108-C00081
         		0.0087
    #2 Step B
    Figure US20010039283A1-20011108-C00082
         		0.0125
  • For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 70 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. [0126]
  • For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify. [0127]
  • Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. [0128]
  • Liquid form preparations may also include solutions for intranasal administration. [0129]
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas. [0130]
  • Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions. [0131]
  • The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose. [0132]
  • Preferably the compound is administered orally. [0133]
  • Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose. [0134]
  • The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg. to 300 mg, according to the particular application. [0135]
  • The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. [0136]
  • The amount and frequency of administration of the compounds of the invention and the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended dosage regimen is oral administration of from 10 mg to 2000 mg/day preferably 10 to 1000 mg/day, in two to four divided doses to block tumor growth. The compounds are non-toxic when administered within this dosage range. [0137]
  • The following are examples of pharmaceutical dosage forms which contain a compound of the invention. The scope of the invention in its pharmaceutical composition aspect is not to be limited by the examples provided. [0138]
    • Pharmaceutical Dosage Form Examples EXAMPLE A
  • [0139]
    Tablets
    No. Ingredients mg/tablet mg/tablet
    1. Active compound 100 500
    2. Lactose USP 122 113
    3. Corn Starch, Food Grade,  30  40
    as a 10% paste in
    Purified Water
    4. Corn Starch, Food Grade  45  40
    5. Magnesium Stearate  3  7
    Total 300 700
    • Method of Manufacture
  • Mix Item Nos. 1 and 2 in a suitable mixer for 10-15 minutes. Granulate the mixture with Item No. 3. Mill the damp granules through a coarse screen (e.g., ¼″, 0.63 cm) if necessary. Dry the damp granules. Screen the dried granules if necessary and mix with Item No. 4 and mix for 10-15 minutes. Add Item No. 5 and mix for 1-3 minutes. Compress the mixture to appropriate size and weigh on a suitable tablet machine. [0140]
    • EXAMPLE B
  • [0141]
    Capsules
    No. Ingredient mg/capsule mg/capsule
    1. Active compound 100 500
    2. Lactose USP 106 123
    3. Corn Starch, Food Grade  40  70
    4. Magnesium Stearate NF  7  7
    Total 253 700
  • Method of Manufacture [0142]
  • Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine. [0143]
  • While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention. [0144]

Claims (24)

What is claimed is:
1. A compound of the formula:
Figure US20010039283A1-20011108-C00083
or a pharmaceutically acceptable salt or solvate thereof, wherein:
a represents N or NO−;
R1 and R3 are the same or different and each represents halo;
R2 and R4 are the same or different and each is selected from H and halo, provided that at least one of R2 and R4 is H;
T is a substituent selected from SO2R or
Figure US20010039283A1-20011108-C00084
Z is O or S;
n is zero or an integer from 1 to 6;
R is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or N(R5)2;
R5 is H, alkyl, aryl, heteroaryl or cycloalkyl.
2. The compound of
claim 1
 having the formula:
Figure US20010039283A1-20011108-C00085
wherein a, T, R1 and R3 are as defined in
claim 1
.
3. The compound of
claim 1
 having the formula:
Figure US20010039283A1-20011108-C00086
wherein a, T, R1, R3 and R4 are as defined in
claim 1
.
4. The compound of
claim 1
 having the formula:
Figure US20010039283A1-20011108-C00087
wherein a, T, R1, R2 and R4 are as defined in
claim 1
.
5. The compound of
claim 1
 having the formula:
Figure US20010039283A1-20011108-C00088
wherein a, T, R1, R2, R3 and R4 are as defined in
claim 1
.
6. The compound of
claim 1
 having the formula:
Figure US20010039283A1-20011108-C00089
wherein a, T, R1, R2, R3 and R4 are as defined in
claim 1
.
7. The compound of
claim 2
, wherein R1 is bromo and R3 is chloro.
8. The compound of
claim 3
, wherein R1 is bromo, R3 is chloro and R4 is bromo.
9. The compound of
claim 4
, wherein R1 is bromo, R2 is bromo and R3 is chloro.
10. The compound of
claim 7
, wherein T is —SO2methyl or a group
Figure US20010039283A1-20011108-C00090
wherein R is a 3-pyridinyl N-oxide, 4-pyridinyl N-oxide, 4-piperdinyl, 3-piperdinyl or 3-pyrrolidinyl group, wherein: the 4-piperdinyl, 3-piperdinyl or 3-pyrrolidinyl groups may be substituted on the piperindinyl or pyrrolidinyl nitrogen with a group R9; R9 is selected from —C(O)N(R10)2, —CH2C(O)N(R10)2, —SO2R10, —SO2N(R10)2, —C(O)R11, —C(O)OR11, alkyl, aryl, aralkyl, cycloalkyl, heterocycloalkyl or heteroaryl; each R10 independently represents H, alkyl, aryl, or aralkyl; and R11 is alkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl.
11. The compound of
claim 8
, wherein T is —SO2methyl or a group
Figure US20010039283A1-20011108-C00091
wherein R is a 3-pyridinyl N-oxide, 4-pyridinyl N-oxide, 4-piperdinyl, 3-piperdinyl or 3-pyrrolidinyl group, wherein: the 4-piperdinyl, 3-piperdinyl or 3-pyrrolidinyl groups may be substituted on the piperindinyl or pyrrolidinyl nitrogen with a group R9; R9 is selected from —C(O)N(R10)2, —CH2C(O)N(R10)2, —SO2R10, —SO2N(R10)2, —C(O)R11, —C(O)OR11, alkyl, aryl, aralkyl, cycloalkyl, heterocycloalkyl or heteroaryl; each R10 independently represents H, alkyl, aryl, or aralkyl; and R11 is alkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl.
12. The compound of
claim 9
, wherein T is —SO2methyl or a group
Figure US20010039283A1-20011108-C00092
wherein R is a 3-pyridinyl N-oxide, 4-pyridinyl N-oxide, 4-piperdinyl, 3-piperdinyl or 3-pyrrolidinyl group, wherein: the 4-piperdinyl, 3-piperdinyl or 3-pyrrolidinyl groups may be substituted on the piperindinyl or pyrrolidinyl nitrogen with a group R9; R9 is selected from —C(O)N(R10)2, —CH2C(O)N(R10)2, —SO2R10, —SO2N(R10)2, —C(O)R11, —C(O)OR11, alkyl, aryl, aralkyl, cycloalkyl, heterocycloalkyl or heteroaryl; each R10 independently represents H, alkyl, aryl, or aralkyl; and R11 is alkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl.
13. The compound of
claim 10
, wherein the carbon in the C-11 position is in the R-configuration.
14. The compound of
claim 11
, wherein the carbon in the C-11 position is in the R-configuration.
15. The compound of
claim 12
, wherein the carbon in the C-11 position is in the R-configuration.
16. The compound of
claim 10
, wherein the carbon in the C-11 position is in the S-configuration.
17. The compound of
claim 11
, wherein the carbon in the C-11 position is in the S-configuration.
18. The compound of
claim 12
, wherein the carbon in the C-11 position is in the S-configuration.
19. A compound of
claim 1
 having the formula:
Figure US20010039283A1-20011108-C00093
20. A method of treating tumor cells expressing an activated ras oncogene comprising administering an effective amount of a compound of
claim 1
.
21. The method of
claim 20
 wherein the tumor cells treated are pancreatic tumor cells, lung cancer cells, myeloid leukemia tumor cells, thyroid follicular tumor cells, myelodysplastic tumor cells, epidermal carcinoma tumor cells, bladder carcinoma tumor cells, colon tumors cells, breast tumor cells and prostate tumor cells.
22. A method of treating tumor cells wherein the Ras protein is activated as a result of oncogenic mutation in genes other than the Ras gene, comprising administering an effective amount of a compound of
claim 1
.
23. A method of inhibiting farnesyl protein transferase comprising the administration of an effective amount of the compound of
claim 1
.
24. A pharmaceutical composition for inhibiting farnesyl protein transferase comprising an effective amount of compound of
claim 1
 in combination with a pharmaceutically acceptable carrier.
US09/825,650 1997-06-17 2001-04-04 Compounds useful for inhibition of farnesyl protein transferase Abandoned US20010039283A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/825,650 US20010039283A1 (en) 1997-06-17 2001-04-04 Compounds useful for inhibition of farnesyl protein transferase
US10/235,027 US6689789B2 (en) 1997-06-17 2002-09-04 Compounds useful for inhibition of farnesyl protein transferase
US10/774,562 US20040157872A1 (en) 1997-06-17 2004-02-09 Compounds useful for inhibition of farnesyl protein transferase

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4985997P 1997-06-17 1997-06-17
US09/094,689 US6239140B1 (en) 1997-06-17 1998-06-15 Compounds useful for inhibition of farnesyl protein transferase
US09/825,650 US20010039283A1 (en) 1997-06-17 2001-04-04 Compounds useful for inhibition of farnesyl protein transferase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/094,689 Division US6239140B1 (en) 1997-06-17 1998-06-15 Compounds useful for inhibition of farnesyl protein transferase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/235,027 Continuation US6689789B2 (en) 1997-06-17 2002-09-04 Compounds useful for inhibition of farnesyl protein transferase

Publications (1)

Publication Number Publication Date
US20010039283A1 true US20010039283A1 (en) 2001-11-08

Family

ID=26727627

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/094,689 Expired - Fee Related US6239140B1 (en) 1997-06-17 1998-06-15 Compounds useful for inhibition of farnesyl protein transferase
US09/825,650 Abandoned US20010039283A1 (en) 1997-06-17 2001-04-04 Compounds useful for inhibition of farnesyl protein transferase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/094,689 Expired - Fee Related US6239140B1 (en) 1997-06-17 1998-06-15 Compounds useful for inhibition of farnesyl protein transferase

Country Status (1)

Country Link
US (2) US6239140B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003120A3 (en) * 2003-06-25 2005-03-17 Schering Corp Metabolites of tricyclic amides useful for inhibition of g-protein function and methods of treatment of proliferative diseases
US20060038551A1 (en) * 2001-04-10 2006-02-23 Picosecond Pulse Labs Ultrafast sampler with coaxial transition

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576639B1 (en) * 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
US6689789B2 (en) * 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
CA2429720C (en) 2000-11-29 2009-12-29 Schering Corporation Tricyclic compounds useful for the inhibition of farnesyl protein transferase
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2497628A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
KR20120035234A (en) 2003-04-11 2012-04-13 메디뮨 엘엘씨 Recombinant il-9 antibodies and uses thereof
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US7517890B2 (en) 2003-11-20 2009-04-14 Children's Hospital Medical Center GTPase inhibitors and methods of use
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
CA2617056A1 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
EA021255B1 (en) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Antagonistic human light-specific human monoclonal antibodies
RU2491094C2 (en) 2007-03-30 2013-08-27 Медиммун, Ллк Antibody preparation
AU2008319298B2 (en) 2007-10-31 2014-07-31 Medimmune, Llc Protein scaffolds
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
AU2013295848B2 (en) 2012-07-25 2018-05-24 Celldex Therapeutics, Inc. Anti-KIT antibodies and uses thereof
US20150231240A1 (en) 2012-10-09 2015-08-20 Igenica Biotherapeutics, Inc. Anti-c16orf54 antibodies and methods of use thereof
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
RS62189B1 (en) 2013-08-26 2021-08-31 Biontech Research And Development Inc Nucleic acids encoding human antibodies to sialyl-lewis a
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2950602C (en) 2014-06-04 2021-07-20 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
CN114230664A (en) 2014-12-11 2022-03-25 皮埃尔法布雷医药公司 anti-C10 ORF54 antibodies and uses thereof
DE112016001013T5 (en) 2015-03-03 2017-12-21 Kymab Limited ANTIBODIES, USES AND METHODS
CN108925136B (en) 2015-12-02 2022-02-01 斯特赛恩斯公司 Antibodies specific for glycosylated BTLA (B and T lymphocyte attenuating factor)
CN109415437B (en) 2015-12-02 2022-02-01 斯特库伯株式会社 Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2018277545A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
CA3065301A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN110997724A (en) 2017-06-06 2020-04-10 斯特库伯株式会社 Methods of treating cancer using antibodies and molecules that bind BTN1A1 or BTN1A 1-ligands
CN111630069B (en) 2017-10-13 2024-05-31 勃林格殷格翰国际有限公司 Human antibodies to Thomsen-non-velle (Tn) antigen
BR112021000934A2 (en) 2018-07-20 2021-04-27 Pierre Fabre Medicament receiver for sight
CN111646982B (en) * 2020-06-04 2023-08-08 浙江凯普化工有限公司 Synthesis method of norketotifen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5393890A (en) 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
NZ251540A (en) 1992-03-27 1996-09-25 Schering Corp Bridged bis-aryl carbinol derivatives, preparation and medicaments
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
JP2875393B2 (en) 1993-10-15 1999-03-31 シェーリング コーポレイション Tricyclic carbamate compounds useful for inhibiting G-protein function and treating proliferative disorders
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Pharmaceutical compositions for inhibition of g-protein function and for treatment of proliferative diseases containing tricyclic compounds some such compounds and process for preparing part of them
US5464840A (en) 1993-12-06 1995-11-07 Schering Corporation Tricyclic derivatives, compositions and methods of use
US5684013A (en) 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5700806A (en) 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases and pharmaceutical compositions comprising them
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
SK86198A3 (en) 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060038551A1 (en) * 2001-04-10 2006-02-23 Picosecond Pulse Labs Ultrafast sampler with coaxial transition
WO2005003120A3 (en) * 2003-06-25 2005-03-17 Schering Corp Metabolites of tricyclic amides useful for inhibition of g-protein function and methods of treatment of proliferative diseases
JP2007516179A (en) * 2003-06-25 2007-06-21 シェーリング　コーポレイション Metabolites of tricyclic amides useful for inhibiting G protein function and methods of treating proliferative diseases
US7271174B2 (en) 2003-06-25 2007-09-18 Schering Corporation Metabolites of tricyclic amides useful for inhibition of G-protein function and methods of treatment of proliferative diseases

Also Published As

Publication number Publication date
US6239140B1 (en) 2001-05-29

Similar Documents

Publication Publication Date Title
US6239140B1 (en) Compounds useful for inhibition of farnesyl protein transferase
US6399615B1 (en) Farnesyl protein transferase inhibitors
US6387905B2 (en) Compounds useful for inhibition of farnesyl protein transferase
US6228865B1 (en) Compounds useful for inhibition of farnesyl protein transferase
US6051582A (en) Compounds useful for inhibition of farnesyl protein transferase
US6124295A (en) Compounds useful for inhibition of farnesyl protein transferase
US6358968B1 (en) N-substituted urea inhibitors of farnesyl-protein transferase
US5877177A (en) Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5925639A (en) Keto amide derivatives useful as farnesyl protein transferase inhibitors
WO1998057960A1 (en) Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
EP1019400B1 (en) Benzo(5,6)cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
EP0931079B1 (en) Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
CA2293712C (en) Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US6071907A (en) Tricyclic compounds useful as FPT inhibitors
US6689789B2 (en) Compounds useful for inhibition of farnesyl protein transferase
EP0991637B1 (en) Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors
EP0993454B1 (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
CA2293372C (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
EP0927179B1 (en) Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
EP0942906B1 (en) Compounds useful for inhibition of farnesyl protein transferase
MXPA99012061A (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
MXPA99012087A (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION